Axalbion is a pharmaceutical company in the clinical development stage that is working on TRPM8 agonists to treat persistent cough and dry eyes, two prevalent and debilitating conditions with limited treatment options. Axalbion has created and investigated new TRPM8 agonists, identifying its primary candidate AX-8. Our compound AX-8 has a quick onset of action and provides innovative topical treatment possibilities by normalizing abnormal cough and lacrimation reflexes and reducing sensory discomfort.